Pliant Therapeutics (PLRX) Share-based Compensation (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Share-based Compensation data on file, last reported at $4.3 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $4.3 million, down 52.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.6 million (down 41.49% YoY), and the FY2025 annual result was $26.2 million, down 30.28% from the prior year.
• Share-based Compensation declined to $4.3 million in Q1 2026 per PLRX's latest filing, from $4.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $13.0 million in Q2 2023 and troughed at $3.4 million in Q2 2022.
• A 5-year average of $8.0 million and a median of $8.9 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation surged 292.16% in 2022, then tumbled 52.27% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $10.9 million in 2022, then slipped by 15.69% to $9.2 million in 2023, then fell by 8.03% to $8.4 million in 2024, then slumped by 46.24% to $4.5 million in 2025, then retreated by 5.99% to $4.3 million in 2026.
• Business Quant data shows PLRX's Share-based Compensation at $4.3 million in Q1 2026, $4.5 million in Q4 2025, and $6.4 million in Q3 2025.